Close Menu
    Facebook X (Twitter) Instagram
    Facebook X (Twitter) Instagram
    BusinessNewsAsia.comBusinessNewsAsia.com
    Subscribe
    • Home
    • Top Stories
    • Business
    • Tech
    • Companies
    • Events
    • Announcements
    BusinessNewsAsia.comBusinessNewsAsia.com
    Home»Clinical Trials»Agilex Biolabs Shares How to Select the Right Bioanalytical Tools for Immuno-oncology and Vaccines Studies – OCT Webinar
    Agilex Biolabs
    Clinical Trials

    Agilex Biolabs Shares How to Select the Right Bioanalytical Tools for Immuno-oncology and Vaccines Studies – OCT Webinar

    Marie JonesBy Marie JonesOctober 19, 2021No Comments4 Mins Read
    Share
    Facebook Twitter LinkedIn Pinterest Email

    Agilex Biolabs, the Australian regulated bioanalytical and toxicology laboratory facilities for clinical trials is presenting a new webinar entitled “Getting it right! Considerations for Immuno-oncology and Vaccine Studies and the Bioanalytical Tools used” in partnership with Outsourcing Clinical Trials (OCT).

    Agilex Biolabs’ Director, Immunoassay, Kurt J. Sales (B.Sc; B.Sc (MED) Hons; M.Sc, Ph.D, PGCM) said:

    “Choosing the right bioanalytical platform for your immunology or vaccines clinical trial is critical to data collection. But navigating the intricate bioanalytical process and selection of assay platforms can be difficult. This webinar covers these platforms in detail and the selection process.”

    Agilex Biolabs is the largest regulated bioanalytical laboratory in Australia with over 24 years’ experience in early phase clinical trials with a track record of enabling the movement of new drug entities to market.

    Agilex Biolabs specialises in pharmacokinetics, pharmacodynamics, and biomarker evaluation, which is key to understanding the drug absorption, distribution, metabolism, and excretion as well as target engagement and efficacy of the drug during clinical development.

    “This webinar will demystify the bioanalytical requirements for clinical studies and will discuss the most common bioanalytical platforms used during clinical trials to measure vaccine responses and levels of inflammatory mediators in biological fluids,” said Dr. Sales.

    Key Learning Objectives
    – Learn how to determine the right bioanalytical platform for your immunology or vaccines clinical trial
    – Understand what do these bioanalytical platforms look like in use
    – Understand the process of selecting the right bioanalytical platform
    – Demystify the bioanalytical requirements for clinical studies

    The webinar will also cover Australian research, and regulatory and clinical infrastructure, which provides a favorable environment for rapid vaccine development. It will also include discussion of a case study for rapid vaccine development based on non-clinical research conducted with a novel COVID-19 protein subunit vaccine.

    Register Here https://bit.ly/3aPlWsx
    Date: 4 November
    Time: 2PM London/3PM CET
    Speaker: Dr Kurt Sales: Director, Immunoassay, Agilex Biolabs

    Agilex Biolabs’ world-class laboratories feature state-of-the-art equipment including Gyrolab Xplore, MSD Quickplex 120, Luminex Magpix, BD FACSymphony A3 flow cytometer and digital droplet quantitative real-time RT-PCR.

    The company offers services for both small molecules and biologics for PK, immunogenicity (PD) and biomarker bioanalysis utilising the two platforms of LC-MS/MS and Immunoassay.

    Australian clinical trials have remained open for business and Agilex Biolabs is a designated essential service so clients can be assured of study continuity.

    Agilex Biolabs has more than 140 staff which includes 85 dedicated laboratory staff, and supports client pharma and biotech companies from US, Europe and APAC.

    Book a confidential briefing with our scientists before you start your next clinical trial. https://calendly.com/agilexbiolabs/30min

    About Agilex Biolabs https://www.agilexbiolabs.com/

    Agilex Biolabs, the Australian specialist bioanalytical and toxicology laboratory facilities for clinical trials, has more than 24 years’ experience in performing regulated bioanalysis, including quality method development, method validation and sample analysis services. It has successfully supported hundreds of preclinical and clinical trials from around the world where customers choose Australia for the streamlined regulatory process and access to the world’s most attractive R&D rebate of more up to 43.5% on clinical trial work conducted in Australia.

    Agilex Biolabs also offers toxicology services through its company TetraQ.

    Agilex Biolabs has the leading certifications including OECD GLP Recognition with NATA (Australian Government OECD GLP Compliance monitoring authority) and ISO 17025 Accreditation for global recognition.

    The company has recently expanded its main labs by more than 30% to accommodate biotech demand from APAC and the USA. In addition it has launched a new Immunobiology lab – watch the video here. https://www.agilexbiolabs.com/launch-of-immunobiology-laboratory/

    Agilex Biolabs specialises in bioanalysis of small molecules and biologics for PK, immunogenicity, biomarkers and immunological pharmacodynamics assessments utilising LC-MS/MS, immunoassay (Mesoscale, Gyrolab, Luminex) and flow cytometry (BD FACSymphony A3, 20 colour cell analyser).

    Agilex offers pharmacodynamics services that include immunobiology services using the latest state-of-the-art technology to support immunology, cell biology and mode of action assays, including:
    – Immunophenotyping
    – Receptor occupancy
    – Cytokine release assays (whole blood or PBMC stimulation assays) and cytokine/biomarker profiling
    – PBMC assays and cellular mechanism of action assays

    Agilex Biolabs Media Contact:
    Kate Newton
    Media@AgilexBiolabs.com

    Agilex Biolabs Immuno-oncology Outsourcing Clinical Trials Vaccines Studies
    Share. Facebook Twitter Pinterest LinkedIn Tumblr Telegram Email
    Previous ArticleEv Dynamics Delivers Over 70 Electric Minibuses to the Philippines
    Next Article Entry into 3-Year Lease for an Industrial Property in Singapore to Commence Production of Lab-Grown Diamonds

    Related Posts

    ERA 2026: HighTide Therapeutics Presents New Findings Supporting HTD1801’s Renoprotective Potential in Oral Presentation

    June 5, 2026

    Everest Medicines Enters Commercialization License Agreement with Mabworks for Bejescin(R) in the Asia-Pacific Market

    June 4, 2026

    Everest Medicines Enters into Exclusive Licensing Agreement with Travere Therapeutics for Civorebrutinib a Potential Best-in-Class BTK Inhibitor for Rare Kidney Diseases, Driving Value Conversion

    June 4, 2026
    Add A Comment

    Comments are closed.

    © 2026 BusinessNewsAsia.com
    • About Us
    • Contact Us
    • BusinessNews.ph
    • AsiaPEVC.com
    • DevFiNews.com
    • RenewableEnergy.ph

    Type above and press Enter to search. Press Esc to cancel.